Search clinical trials for: 3,4 Diaminopyridine

Total 226 results

Lahey Clinic

Approved for marketing

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) (LEMS)

Lambert-Eaton Myasthenic Syndrome | Congenital Myasthenic Syndrome

United States
Catalyst Pharmaceuticals, Inc.

Terminated

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Myasthenia Gravis, MuSK | AChR Myasthenia Gravis

United States, Italy
David P. Richman, MD
Jacobus Pharmaceutical

No longer available

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

Lambert Eaton Myasthenic Syndrome

United States
Ricardo Maselli
Catalyst Pharmaceuticals, Inc.

No longer available

Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia

Congenital Myasthenic Syndrome

United States
Vern C. Juel, M.D.

No longer available

Treatment Use of 3,4-Diaminopyridine

Myasthenic Syndromes, Congenital

United States
Jacobus Pharmaceutical

Completed

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (DAPPER)

Lambert-Eaton Myasthenic Syndrome | Eaton-Lambert Myasthenic Syndrome

United States
UMC Utrecht
Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Completed

The NeXT Study; The Netherlands XTC Toxicity Study

Psychopathology | Ecstasy (Drug) | N-Methyl-3,4-Methylenedioxymethamphetamine

Netherlands
Catalyst Pharmaceuticals, Inc.

No longer available

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome (EAP-001)

Lambert-Eaton Myasthenic Syndrome | Congenital Myasthenic Syndrome | Nystagmus, Acquired

United States
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis

Multiple Sclerosis

France
The Cleveland Clinic

No longer available

Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)

Lambert-Eaton Myasthenic Syndrome

United States
Assistance Publique - Hôpitaux de Paris

Terminated

DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome (DAPREB)

Brugada Syndrome

France
David Lacomis, MD
Jacobus Pharmaceutical

No longer available

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

Lambert-Eaton Myasthenic Syndrome
University Hospital, Basel, Switzerland

Active, not recruiting

Effects of MDMA-like Substances in Healthy Subjects (MDMA-like)

Healthy

Switzerland
University Hospital, Basel, Switzerland

Completed

Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)

Substance-Related Disorders | Amphetamine-Related Disorders | Mood Disorder

Switzerland
University Hospital, Basel, Switzerland
Heffter Research Institute

Completed

Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)

Substance-Related Disorders | Amphetamine-Related Disorders | Mood Disorder

Switzerland
California Pacific Medical Center Research Institute
National Institute on Drug Abuse (NIDA); University of California, San Francisco

Completed

Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine] (MDA)

Healthy

United States
FDA Office of Orphan Products Development
Duke University

Completed

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

Lambert-Eaton Myasthenic Syndrome
Oregon Health and Science University
Jacobus Pharmaceutical

No longer available

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Lambert-Eaton Myasthenic Syndrome (LEMS) | Congenital Myasthenia (CM)

United States
Parc de Salut Mar
Instituto de Salud Carlos III

Completed

Abuse Liability and Human Pharmacology of Mephedrone

Amphetamine-Related Disorders

Spain
University Hospital, Basel, Switzerland

Completed

Acute Effects of R- and S-MDMA in Healthy Subjects (R-S-MDMA)

Healthy

Switzerland
Spaulding Rehabilitation Hospital
Multidisciplinary Association for Psychedelic Studies

Not yet recruiting

MDMA-assisted Therapy for Fibromyalgia

Fibromyalgia

United States
Dr. Leslie Morland
San Diego Veterans Healthcare System; Healing Breakthrough; Lykos Therapeutics

Recruiting

MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD (MDMA-bCBCT)

PTSD | Relational Problems

United States
University of Colorado, Denver

Approved for marketing

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome (3 4-DAP)

Lambert Eaton Myasthenic Syndrome

United States
National Center for Research Resources (NCRR)
Mayo Clinic

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Centre Hospitalier Universitaire, Amiens

Completed

Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism

Botulism

France
University Hospital, Basel, Switzerland

Recruiting

Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose

Healthy

Switzerland
Healing Breakthrough
San Diego Veterans Healthcare System; National Center for PTSD; White River Junction... and other collaborators

Not yet recruiting

MDMA-assisted Massed Prolonged Exposure for PTSD (MDMA-PE)

Post-Traumatic Stress Disorder

United States
University Hospital, Basel, Switzerland

Completed

Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)

Substance-related Disorders | Mood Disorder | Amphetamine-related Disorders

Switzerland
Catalyst Pharmaceuticals, Inc.

Completed

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Lambert Eaton Myasthenic Syndrome

United States, Spain, Serbia, Russian Federation, Hungary, France, Germany, Poland
Jeffrey A. Cohen, MD
Jacobus Pharmaceutical

Terminated

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) (3-4DAP)

Muscle Weakness

United States
Lykos Therapeutics
Swiss Medical Association for Psycholytic Therapy

Completed

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

Posttraumatic Stress Disorder

Switzerland
Germans Trias i Pujol Hospital
Fundació Recerca Institut Germans Trias i Pujol; Istituto Superiore di Sanità

Active, not recruiting

Abuse Potential and Human Pharmacology of Methylone (METI/FIS/1)

Healthy Subjects | Substance Use

Spain
Universitätsmedizin Mannheim
German Research Foundation

Unknown

Clinical Study on Implicit Learning, Comorbidity and Stress Vulnerability in Chronic Functional Pain

Irritable Bowel Syndrome | Fibromyalgia

Germany
The Institutes for Pharmaceutical Discovery, LLC
Covance; Mars, Inc.

Completed

Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans

ADME

United States
VA Loma Linda Health Care System
Multidisciplinary Association for Psychedelic Studies

Recruiting

MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD (VALLMDMA_001)

Post Traumatic Stress Disorder | Combat Stress Disorders

United States
Lykos Therapeutics

Not yet recruiting

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Pharmacokinetics | Hepatic Impairment

United States
Lykos Therapeutics

Completed

Food Effects on Bioavailability of MDMA in Healthy Volunteers (MPKF)

Pharmacokinetics

United States
Alan Nichol

Completed

Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study

Cancer (High-grace Glioma)

Canada
University Hospital, Basel, Switzerland

Completed

Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls (OxyMA)

Diabetes Insipidus

Switzerland
Foundation for Liver Research

Completed

Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB (PEGON)

Chronic Hepatitis B

Netherlands, China
Sunstone Medical

Recruiting

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Cancer | Adjustment Disorders

United States
Lykos Therapeutics

No longer available

A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD (EAMP1)

Post Traumatic Stress Disorder

United States
MAPS Europe B.V.
Multidisciplinary Association for Psychedelic Studies

Completed

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

PTSD

Czechia, Germany, Netherlands, Norway, United Kingdom
Lykos Therapeutics

Not yet recruiting

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)

Psychological Effects of Study Drug
Lykos Therapeutics

Completed

Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

PTSD

United States
Lykos Therapeutics

Completed

Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

Posttraumatic Stress Disorder

United States
Bronx VA Medical Center

Not yet recruiting

Dose Optimization of MDMA-Assisted Therapy for PTSD (DosOp)

Posttraumatic Stress Disorder
Lykos Therapeutics

Withdrawn

Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD (NUMCAP1)

Posttraumatic Stress Disorder
Lykos Therapeutics

Completed

Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD

Posttraumatic Stress Disorder

United States
Lykos Therapeutics

Completed

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD (MAPPUSX)

PTSD

United States, Canada, Israel

Search clinical trials for: 3,4 Diaminopyridine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations